CAR-T ENX (Beijing Yongtai Ruike Biotechnology)

N/A

Report date: 2023/11/13 10:54:06

Base Information

Drug NameCAR-T ENX (Beijing Yongtai Ruike Biotechnology)
Drug Alias NameCAR-T-ENX
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionHistone-lysine N-methyltransferase EZH1 inhibitorsHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH1Histone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Yongtai Rec Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Yongtai Rec Biotechnology Co LtdImmunotech Applied Science Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A